Tony Coles, Cerevel Therapeutics CEO
November 8, 2022 11:02 AM EST
Financing
R&D

While PhI­II Parkin­son's tri­als go slow­er than ex­pect­ed, Cerev­el pre­views plans to raise $900M

Amber Tong

Tony Coles set out to build “the pre­mier neu­ro­science com­pa­ny” at Cerev­el. And that means putting fundrais­ing plans in place well in ad­vance.

Just weeks …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times